SANGAMO THERAPEUTICS, INC 10-Q — AI Bull & Bear Analysis

The latest 10-Q paints a picture of a company in a race against time, where scientific validation is clashing with financial exhaustion. Sangamo possesses a legitimate technological edge in genomic medicine and a promising regulatory path for its Fabry program, yet these assets are currently overshadowed by an acute liquidity crisis. The transition to the OTCQB market further complicates its ability to raise the equity needed to survive until a potential BLA approval or partnership deal. Ultimately, the investment thesis hinges on whether Sangamo can secure a commercialization partner for its Fabry program in the very near term. A successful deal would resolve the going concern uncertainty and provide the capital necessary to monetize its platform. However, failure to secure such a partner by the third quarter of 2026 would likely leave the company with no choice but to liquidate assets or file for bankruptcy, regardless of the clinical merit of its pipeline.